Abstract: Provided are a type XVIII crystal of compound (3), and a preparation method therefor, a composition containing the crystal, and the use thereof. The type XVIII crystal shows good physical properties, such as easily prepared and crystal form stability, which is convenient for large-scale production and quality control of drugs, and is suitable as a crystal form of compound (3) in drug preparation.

Abstract: The present invention relates to the field of medicinal chemistry, and provides a crystal of 4?-substituted nucleoside, a preparation method therefor, a composition containing the crystal, and a use thereof. The crystal of the 4?-substituted nucleoside is a type-III crystal of compound (3). The type-III crystal shows excellent physical properties, such as easy preparation, stable crystal form and the like, and is convenient for large-scale production and quality control of drugs. The type-III crystal is suitable as a crystal form of compound (3) in drug preparation.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Abstract: The present invention relates to a method for preventing or treating a coronavirus infectious disease, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound represented by formula (I) or pharmaceutically acceptable salts thereof. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in all of the clearance rate by viral nucleic acid test, the course of clearance, and the cure and discharge time.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: The present invention discloses a crystal form, a preparation method and an application of a 4?-substituted nucleoside compound I having the following structure, including salts, prodrugs, and compositions thereof. Animal pharmacokinetic studies demonstrated that the effective drug concentrations of Compound Ia and Compound Ig in HIV target cells, peripheral blood mononuclear cells (PBMC), were effective in inhibiting HIV replication after 7 and 5 days, respectively. Therefore, Compound I can be used as a long-acting drug for preventing and treating AIDS. R is selected from ethynyl, azide, and cyano groups, X is selected from hydrogen and fluorine, and B is selected from B1 and B2.

Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Abstract: A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R1 is a C2-10 alkyl, C2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

Abstract: A 2-(2,4,5-substituted phenylamino) pyrimidine derivative, having the following chemical formula I:

Abstract: A crystalline form A of a compound I is a monoclinic system and a space group thereof is p21.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Abstract: The disclosure relates to a thienopyrimidinone derivative, or a pharmaceutically acceptable prodrug, salt, and solvate thereof. The derivative has the formula (I), where R represents hydrogen (H) or deuterium (D); R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.

Abstract: A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R1 is a C2-10 alkyl, C2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-ß-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: The disclosure relates to a thienopyrimidinone derivative, or a pharmaceutically acceptable prodrug, salt, and solvate thereof. The derivative has the formula (I), where R represents hydrogen (H) or deuterium (D); R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.